Acute Ischemic Stroke Clinical Trial
Official title:
The Efficacy and Safety Study of Thrombus Aspiration Catheter(Ton-bridgeMT) on Endovascular Treatment of Acute Ischemic Stroke
This is a prospective multicenter, single-arm objective performance criteria trial to assess the efficacy and safety of the the thrombus aspiration catheter.
Status | Not yet recruiting |
Enrollment | 155 |
Est. completion date | August 2023 |
Est. primary completion date | June 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Age =18 years; - Baseline NIHSS score =6; - Subject has acute occlusion located in Vertebral artery(VA) / Internal Carotid Artery (ICA) / M1or M2 segment of Middle Cerebral Artery (MCA) / Basilar artery (BA) diagnosed by DSA; - Femoral artery puncture is expected to be completed within 24 hours of onset; - mRS score= 2; - Subject or legal representative is able to understand the purpose of study, agrees to comply with protocol requirements and has provided written informed consent. Exclusion Criteria: - Chronic occlusion in the target area; - Epilepsy at the time of stroke; - Bleeding from the gastrointestinal or urinary system in the past three weeks; - After drug control, systolic blood pressure was greater than 185mmhg and / or diastolic blood pressure was greater than 110mmhg; - International Normalized Ratio(INR)>3; - Random blood glucose < 2.7mmol/L or > 22.2mmol/L; - Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors, - systemic infection, active disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe mental illness); - Tortuous lesion / severe stenosis in the starting segment of the carotid artery / Carotid dissection / Arteritis judged by researchers that is not suitable for the procedure; - Acute occlusion of bilateral carotid arteries; - Intracranial hemorrhage or massive infarction diagnosed by CT or MR; - History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast agents; - Expected life <12 months; - Female subjects who are pregnant or planning to become pregnant or lactate within the study period; - Subject has participated in any other drug or medical device clinical trials in 1 month before signing informed consent; - Other circumstances judged by researchers that are not suitable for enrollment . |
Country | Name | City | State |
---|---|---|---|
China | Xuanwu hospital Capital Medical University | Beijing | |
China | Cangzhou central hospital | Cangzhou | Hebei |
China | Hunan Provincial People's Hospital | Changsha | Hunan |
China | School of medicine UESTC | Chengdu | Sichuan |
China | Ganzhou Municipal Hospital | Ganzhou | Jiangxi |
China | The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang |
China | The First Affiliated Hospital of USTC | Hefei | Anhui |
China | Central Hospital Affiliated to Shangdong First Medical University | Jinan | Shandong |
China | First People's Hospital of Jinan | Jinan | Shandong |
China | The Second People's Hospital of Liaocheng | Liaocheng | Shandong |
China | The Second Nanning People's hospital | Nanning | Guangxi |
China | Rizhao central Hospital | Rizhao | Shandong |
China | Shanxi Candiovascular hospital | Taiyuan | Shanxi |
China | Zhuhai people's hospital | Zhuhai | Guangdong |
China | Zigong Third People's Hospital | Zigong | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Zhuhai Tonbridge Medical Tech. Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful recanalization rate within three-times aspiration | Successful recanalization is defined as modified Thrombolysis In Cerebral Infarction scale(mTICI) 2b or 3 evaluated by Digital subtraction angiography (DSA). | Up to 90 days | |
Secondary | Successful recanalization rate within three-times aspiration | Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA. | Intraoperation | |
Secondary | Successful recanalization rate beyond three-times aspiration | Successful recanalization is defined as mTICI 2b or 3 evaluated by DSA. Auxiliary device such as stent could be used. | Intraoperation | |
Secondary | National Institute of Health stroke scale(NIHSS) | NIHSS score in 72 hours and 7 days(or the day when patients discharged, depends on which day is earlier) will be compared. | 72 hours / 7 days | |
Secondary | Rate of Modified Rankin Scale(mRS) score less than 3 | The mRS score is assessed in 90 days follow-up. | 90 days | |
Secondary | Device delivery performance | Device delivery performance including transport and pullback performance, which is ranked excellent/good/normal/bad. | Intraoperation | |
Secondary | The rate of symptomatic intracranial hemorrhage | National Institute of Health stroke scale(NIHSS) increased by at least 4 compared with the baseline. | 72 hours | |
Secondary | Death rate | Subjects who died from any cause would be counted. | Up to 90 days | |
Secondary | The rate of AE | The definition of AE(Adverse Event) refers to ISO 14155 | Up to 90 days | |
Secondary | The rate of SAE | The definition of SAE (Serious Adverse Event) refers to ISO 14155 | Up to 90 days | |
Secondary | The rate of medical device deficiency | Medical device deficiency refer to the unreasonable risks of medical devices that may endanger human health and life safety under normal use in the process of clinical trials, such as label errors, quality problems, malfunctions, etc. | Up to 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 | |
Completed |
NCT00963989 -
Imaging Guided Patient Selection for Interventional Revascularization Therapy
|
N/A | |
Completed |
NCT01021319 -
Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)
|